AUTHORS
Mazyar Shadman, MD, MPH, Annamaria Frustaci, MD2, Chan Cheah, MBBS, DMSc3, Constantine S. Tam, MD,MBBS4, John F. Seymour, MBBS, PhD5, Ricardo Daniel Parrondo, MD6, Damien Roos Weil, MD7, Eugen Tausch, MD, PhD8, Georg Hess, MD9, Barbara Eichhorst, MD10, Herbert Eradat, MD, MS11, Yanan Zhang12, Linlin Xu13, Kaiyuan Hua14, Shannon Fabre15, Motohisa Takai16, Shelonitda Rose17, Judith Trotman, FRACP, FRCPA, MBChB18
AFFILIATIONS
1 Fred Hutchinson Cancer Center, Seattle, WA, United States, University of Washington, Seattle, WA, United States
2 ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
3 Linear Clinical Research, Nedlands, WA, Australia, Medical School, University of Western Australia, Crawley, WA, Australia, Sir Charles Gairdner Hospital, Nedlands, WA, Australia
4 Alfred Hospital and Monash University, Melbourne, VIC, Australia
5 Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC, Australia
6 Mayo Clinic - Jacksonville, Jacksonville, FL, United States
7 Pitié-Salpêtrière Hospital, Paris, France
8 Ulm University, Ulm, Germany
9 Department of Hematology and Medical Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
10 Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, University of Cologne, Cologne, Germany
11 David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
12 BeOne Medicines, Ltd, San Carlos, CA, United States
13 BeOne Medicines, Ltd, San Carlos, CA, United States
14 BeOne Medicines, Ltd, San Carlos, CA, United States
15 BeOne Medicines, Ltd, San Carlos, CA, United States
16 BeOne Medicines, Ltd, San Carlos, CA, United States
17 BeOne Medicines, Ltd, San Carlos, CA, United States
18 Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia
ABSTRACT
Introduction: BTK is a key mediator of signaling pathways involved in the pathogenesis of WM. Tacabrutideg (BGB-16673) is a potential first-in-class BTK degrader that induces BTK degradation through the proteasome pathway, leading to tumor regression. Here we report updated safety and efficacy results of tacabrutideg in patients (pts) with R/R WM in phase 1 of the ongoing open-label, phase 1/2 CaDAnCe-101 study (BGB-16673-101; NCT05006716).
Methods: Eligible pts had confirmed R/R WM (≥2 prior therapies), an ECOG performance status of 0-2 (EU: 0/1), and prior treatment with an anti-CD20 antibody and covalent BTK inhibitor (BTKi). Tacabrutideg was administered orally once daily. Primary objectives were the safety/tolerability (National Cancer Institute Common Terminology Criteria for Adverse Events v5.0), maximum tolerated dose, and recommended dose for expansion. Key secondary objectives were the overall response rate (ORR, ≥minor response; International Workshop on WM 11 consensus criteria) and major response rate (MRR; ≥partial response).
Results: As of March 25, 2026, 43 pts with R/R WM had received tacabrutideg (100 mg, n=15; 200 mg, n=15; 350 mg, n=13). Median age was 72 (range, 46-81) years, and median number of prior therapies was 3 (range, 2-11); these included an anti-CD20 antibody (n=43 [100%]), covalent BTKi (n=43 [100%]), noncovalent BTKi (n=7 [16.3%]), BCL2 inhibitor (n=10 [23.3%]), chemotherapy (n=40 [93.0%]), and proteasome inhibitor (n=14 [32.6%]). Thirty-six pts (83.7%) discontinued prior BTKi due to progressive disease (PD). At baseline, the frequencies of gene mutations in WM cells (42 evaluable pts) were 19 (45.2%) for CXCR4, 23 (54.8%) for TP53, 13 (31.0%) for BTK, and 3 (7.1%) for PLCG2. Median study follow-up was 17.5 (range, 0.8-40.6) months. At data cutoff, 22 pts (51.2%) remained on treatment.
Median tacabrutideg exposure was 15.5 (range, 0.3-38.0) months. Overall, 97.7% of pts experienced any-grade treatment-emergent adverse events (TEAEs; grade ≥3, 69.8%). Any-grade TEAEs in ≥25% were neutropenia/neutrophil count decreased (37.2%), diarrhea (30.2%), and contusion (bruising; 27.9%). Examining the frequencies of new or ongoing any-grade TEAEs during the time period of 0 to <12 months compared with 12 to <24 months, the rates of neutropenia/neutrophil count decreased (37.2% vs 11.5%) and diarrhea (27.9% vs 19.2%) decreased in the second year, respectively. Grade ≥3 TEAEs in ≥10% included neutropenia/neutrophil count decreased (34.9%) and anemia (14.0%). No atrial fibrillation occurred. As previously reported, 3 pts (7.0%) died due to TEAEs.
All 43 pts were response-evaluable. The ORR was 81.4% (n=35), the MRR was 74.4% (n=32), and the very good partial response rate was 30.2% (n=13). Median time to first overall response was 1.0 (range, 0.9-6.5) months and time to best overall response was 2.1 (range, 0.9-12.2) months. High ORRs and MRRs were observed in pts with disease bearing mutations in the following genes: CXCR4 (94.7% [18/19] and 84.2% [16/19], respectively), TP53 (both 87.0% [20/23]), BTK (both 100% [13/13]), and PLCG2 (both 66.7% [2/3]). High ORR was observed in 77.8% (28/36) of pts who discontinued a prior BTK inhibitor due to PD. Pts with baseline anemia and treatment responses had rapid improvement in hemoglobin levels, from a median of 97.5 (range, 60.0-108.0) g/L at baseline (n=24) to 114.0 (range, 88.0-143.0) g/L at week 9 day 1 (n=23). Pts with baseline hypoalbuminemia (<35 g/L) and treatment responses had improvement in albumin levels from a median of 31.5 (range, 21-34.2) g/L at baseline (n=22) to 37 (range, 23-45) g/L at week 9 day 1 (n=19). The duration of response at 18 months was 71.7% among pts achieving ≥minor response (median follow-up in responders, 18.4 months). Median progression-free survival (PFS) follow-up was 19.3 (95% CI, 16.6-22.1) months; the estimated 18-month PFS rate was 68.4% (95% CI, 50.9%-80.7%).
Conclusions: Tacabrutideg had promising antitumor activity, including in pts with R/R WM bearing CXCR4, TP53, and BTK mutations. Pts with treatment responses experienced rapid improvement in cytopenia and hypoalbuminemia, and response was sustained over time. No new safety signals or TEAE-related deaths occurred in heavily pretreated pts with R/R WM in CaDAnCe-101. Phase 2 of this study is enrolling in pts with WM.
DISCLOSURES
Mazyar Shadman, MD, MPH: Koi Biotherapeutics - Current holder of stock options in a privately-held company; Koi Biotherapeutics - Current holder of stock options in a privately-held company; Koi Biotherapeutics - Current equity holder in private company; Janssen - Research Funding; AstraZeneca - Research Funding; Sana Biotechnology - Research Funding; Nurix - Research Funding; Genmab - Research Funding; Genentech - Research Funding; Morphosys/Incyte - Research Funding; AbbVie - Research Funding; Beigene - Research Funding; Genmab - Research Funding; Incyte - Research Funding; Vincerx - Research Funding; Mustang Bio - Research Funding; Merck - Research Funding; AstraZeneca - Research Funding; BeOne Medicines - Research Funding; Legend Bio - Research Funding; AbbVie - Research Funding; Genetech - Research Funding; Genmab - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Ascentage Pharma - Consultancy (Includes expert testimony); Mustang Bio - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Genetech - Consultancy (Includes expert testimony); Pierre Fabre - Consultancy (Includes expert testimony); Legend Bio - Consultancy (Includes expert testimony); Fate Therapeutics - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Kite, A Gilead company - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Morphosys/Incyte - Consultancy (Includes expert testimony); Kite Pharma - Consultancy (Includes expert testimony); Fate therapeutics - Consultancy (Includes expert testimony); BeOne Medicines - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony)